Figure 7. NSC 47147 inhibits FADD phosphorylation in an A549-FKR xenograft model and sensitizes tumors to an apoptotic stimulus.

(A) Athymic nude mice bearing A549-FKR expressing xenografts were treated with vehicle control (DMSO) or NSC 47147 (0.5 mg/kg) by i.p. injection. Mice were imaged for bioluminescence at the indicated times. Relative luminescence was calculated as the ratio of bioluminescence at each time point to the basal bioluminescence prior to treatment. Data points represent mean relative luminescence ± SEM. (B) Representative bioluminescence images of tumor-bearing mice prior to treatment (basal) and 3, 6 and 18 hours post–treatment with NSC 47147 (0.5 mg/kg) . (C) Tumor-bearing mice were treated with 3 mg/kg NSC 47147 once daily for 8 days and/or 2 mg/kg cisplatin on days 1 and 7 by i.p injection and tumor volume calculated through day 13. Data are plotted as mean relative tumor volume ± SEM. (D) Immunohistochemical staining of A549-FKR xenografts after once-daily treatment for 4-days with 3 mg/kg NSC 47147 and/or 2 mg/kg cisplatin. Tumors were harvested and fixed on day 4; sections were stained for apoptosis as described in materials and methods. Figure shows duplicate images of representative fields.